FDA Clearance Tracker · P200035-S002
OrganOx metra® System
Last checked: Nov 20, 2026Latest source record: May 27, 2022 (this decision)Source: openFDAMethods & limitations
Decided
May 27, 2022
Approved
Time to decision
67 days
Received Mar 21, 2022. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P200035-S002
- Device name
- OrganOx metra® System
- Applicant
- Organox Limited
- Applicant location
- Oxford
- Received
- Mar 21, 2022
- Decided
- May 27, 2022
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P200035
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for the OrganOx metra® New Enrollment PAS. The OrganOx metra® New Enrollment PAS is a multi-center, single-arm, unblinded post-approval study designed to compare recipients of PAS NMP livers versus IDE SCS livers with respect to adverse biliary-related events. Recruitment will take place at a minimum of 10 sites which are UNOS member liver transplant centers.
Source documents
Other decisions for Organox Limited
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P200035 · Decided Dec 9, 2021 · 512 days after receipt
Device type: Normothermic machine perfusion system for the preservation of donor livers prior to transplantation (QQK) · GI, Urology & Nephrology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.